Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 5/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 5/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18919147 | 0.94 | MAPT (0.56) | MAPTKMT2AALDH1A1HTR2ADRD2 | |
| SCHEMBL18919079 | 0.94 | MAPT (0.63) | MAPTKMT2AALDH1A1DRD2SIGMAR1 | |
| SCHEMBL18919216 | 0.91 | MAPT (0.62) | MAPTKMT2AALDH1A1DRD2SIGMAR1 | |
| SCHEMBL18919127 | 0.88 | RXFP1 (0.56) | MAPTKMT2AALDH1A1DRD2DRD3 | |
| SCHEMBL18919126 | 0.88 | MAPT (0.59) | MAPTKMT2AALDH1A1HTR2ADRD2 | |
| SCHEMBL18889384 | 0.83 | POLB (0.60) | MAPTKMT2AHTR2ADRD2DRD3 | |
| SCHEMBL18919161 | 0.82 | PIKFYVE (0.51) | MAPTKMT2AALDH1A1HTR2ADRD2 | |
| SCHEMBL18919163 | 0.82 | PIKFYVE (0.51) | MAPTKMT2AALDH1A1HTR2ADRD2 | |
| SCHEMBL17444659 | 0.81 | POLB (0.60) | KMT2AHTR2ADRD2DRD3RAB9A | |
| SCHEMBL18889385 | 0.81 | POLB (0.58) | MAPTKMT2ADRD2DRD3RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170157135-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | NOVOGEN LIMITED (AU) | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157135-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | TPM3, TPM4, TNNI3 | MAPT 2167/4885KMT2A 2215/4885ALDH1A1 1080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.